McNeil Chooses Litigation To Challenge Glaxo’s OTC Flonase Ad Claims
This article was originally published in The Tan Sheet
The J&J consumer products subsidiary, which markets the Zyrtec and Benadryl OTC allergy lines, foregoes industry self-regulation channels to hasten a decision in its challenge of Glaxo’s recently launched Flonase Allergy Relief.
You may also be interested in...
FDA grants Glaxo market exclusivity for OTC as the first OTC fluticasone product, but with a label carve-out that limits exclusivity to the indication of “OTC use for temporary relief of ocular symptoms due to hay fever or other upper respiratory allergies.”
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.